What people mean by BPC-157 and TB-500
People often say the two names in one breath. They are different substances. Neither is an FDA-approved drug.
BPC-157 is a synthetic fragment related to a body-protection compound studied mainly in animals. TB-500 is the name people use for a thymosin-beta-4 fragment. That is the naming, not a mechanism, and not a healing claim.
At the July 23, 2026 meeting of FDA’s Pharmacy Compounding Advisory Committee, the committee recommended both for the 503A Bulks List, 8–6 with 1 abstention. FDA staff had recommended against. The vote does not legalize compounding and does not approve either drug.
BPC-157 was evaluated at that meeting for ulcerative colitis. TB-500 was evaluated for wound healing. Those are the uses the committee discussed — not a menu of what to take.
A tracker can hold the name you logged. It cannot tell you what to take. The news write-up is here: An FDA panel voted on six peptides. That is not approval.
Citations
- FDA briefing introduction
- FDA BPC-157 briefing
- FDA introductory remarks, July 23
- AJMC recap
- McDermott law recap
- Mintz: what the vote does and does not do
Peptide Vault is a personal log and research library. Not medical advice, not a pharmacy, not a shop. We do not tell you what to take, how to mix it, or where to get it. No dosing. No where-to-buy. No mix tutorials. No heal/optimize claims.